SCHEDULE 13G/A: Janus Henderson Group PLC Amends Stake in Ligand Pharmaceuticals, Maintains Over 5% Beneficial Ownership
Beneficial Ownership Disclosure
Janus Henderson Group PLC has filed an Amendment No. 7 to its Schedule 13G, disclosing a 5.3% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of March 31, 2025.
Summary
- Janus Henderson Group PLC, a Jersey-based parent holding company and investment adviser, filed an Amendment No. 7 to its Schedule 13G regarding its beneficial ownership in Ligand Pharmaceuticals Incorporated.
- As of March 31, 2025, Janus Henderson Group PLC beneficially owns 1,028,066 shares of Ligand Pharmaceuticals' Common Stock.
- This represents 5.3% of the class of Ligand Pharmaceuticals' Common Stock.
- Janus Henderson Group PLC's indirect subsidiary, JHIUS, is deemed the beneficial owner of 985,808 shares, representing 5.1% of the class, with shared voting and dispositive power over these shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing beneficial ownership, containing factual information without expressing positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing indicates continued institutional investment interest in the pharmaceutical sector, specifically in Ligand Pharmaceuticals, by a major asset manager like Janus Henderson Group PLC. It reflects ongoing portfolio management activities within the investment advisory industry.
Stakeholder Impact
- This filing primarily impacts shareholders of Ligand Pharmaceuticals by providing transparency on significant institutional ownership, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date Power of Attorney was executed by Janus Henderson Group plc. |
| 2025-03-31 | Date of event which requires filing of this statement (beneficial ownership reporting date). |
| 2025-05-14 | Date of filing and signature for the Schedule 13G Amendment No. 7. |
Keywords
Ligand Pharmaceuticals, Janus Henderson Group PLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Pharmaceuticals, Investment Adviser, Holding Company
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.